Ribonexus (formerly Aglaia Therapeutics) is developing oncology therapies aimed at restoring sensitivity to current targeted treatments in patients who have developed resistance. Its core programme targets melanoma and centers on an eIF4A inhibitor approach. The company plans to use clinical data from that programme to seek licence agreements with pharmaceutical or biopharma partners. Ribonexus intends to assess and expand its early-stage oncology pipeline beyond melanoma to other cancer indications. The firm recently entered a partnership with the pharmaceutical group Pierre Fabre, which company leadership cites as validation of the pipeline’s potential. The company received new public funding to advance its development programmes.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2022